Coverage of stories discussed this week on ascopost.com:

Germline RABL3 Mutation May Increase Risk of Pancreatic Cancer Development

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration. We also talk about a report from the World Health Organization on tobacco use worldwide. Then, we discuss two recent FDA approvals in prostate cancer and a rare joint tumor.

Coverage of stories discussed this week on ascopost.com:

Erdafitinib in FGFR Altered Advanced Urothelial Carcinoma

WHO Releases Report on the Global Tobacco Epidemic

FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor

This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer. 

We also talk about a study that examined the relationship between the duration of chemotherapy and body mass index and the development of lymphedema in some patients with breast cancer.

Lastly, we present three recent approvals and regulatory communications from the FDA.

Coverage of stories discussed this week on ascopost.com:

Overall Survival With the Addition of Ribociclib to Endocrine Therapy in Advanced HR-Positive, HER2-Negative Breast Cancer

Neoadjuvant Chemotherapy Duration and Obesity May Be Associated With Increased Risk of Lymphedema in Some Women With Breast Cancer

FDA Approves Rituximab Biosimilar for Non-Hodgkin Lymphoma, CLL, and Autoimmune Conditions

FDA Requests Manufacturer Recall of Some Textured Breast Implants

FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer

This week, we discuss a study that found a disconnect between rates of colonoscopy and recent increases in colorectal cancer incidence in younger adults.

In addition, Dr. Kimmie Ng, of Dana-Farber Cancer Institute, offers her insights on the rising rates of colorectal cancer in young adults.Then, we turn to a report on the relationship between androgen-deprivation therapy and rates of Alzheimer disease and dementia in elderly patients with prostate cancer.

Coverage of stories discussed this week on ascopost.com:

Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends

Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients

This week, we discuss long-term results from an extended analysis of the National Lung Screening Trial, and Dr. James Mulshine of Rush University offers his thoughts on these findings. 

We also review a report on radioactive iodine treatment for hyperthyroidism and long-term risk of death from solid cancers.

Coverage of stories discussed this week on ascopost.com:

Extended Follow-up From the National Lung Screening Trial Reported

Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?

We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.

Coverage of stories discussed this week on ascopost.com:

BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAFV600E–Mutated Metastatic Colorectal Cancer

REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer

Chronic Pain in U.S. Cancer Survivors

Coverage of stories discussed this week on ascopost.com:

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma

In this episode, we discuss news from the Annual Congress of the European Hematology Association in multiple myeloma, catch up on a study presented at ASCO on gastric cancer, and review a recently published paper on prostate cancer development in World Trade Center first responders.

Coverage of stories discussed this week on ascopost.com:

EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple Myeloma

Exposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders

In this episode, we discuss more news from the ASCO Annual Meeting, including findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week.

Coverage of stories discussed this week on ascopost.com:

Discrimination, Gender Bias in Oncology Training and Professional Meetings 

FDA Approves New Trastuzumab Biosimilar

FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies